Please upgrade your browser.
The discovery, which was described in a paper published Wednesday, was studied in a common type of kidney cancer cell, but it could apply to tumors in other parts of the body as well.
A team around Auckland Cancer Society Research Centre (ACSRC) associate professor Michael Hay including researchers at the Maurice Wilkins Centre for Molecular Biodiversity and Stanford has designed a compound known as STF-31 that starves certain cancer cells of glucose, depriving them of energy.
Although whole brain radiation therapy (WBRT) has been a standard palliative management for brain metastases from renal cell carcinoma, its benefit has been elusive because of radiobiological resistance.
A mother-of three who repeatedly visited her GP suffering from breathlessness over seven months was finally sent for an X-ray... which revealed a tumour the size of a football in her chest.
When was the last time you updated your family cancer history at the doctors office? If its been more than 5 or 10 years, you may want to inform your doctor of any changes.
The authors report a case with a complete pathologyproven remission after sunitinib treatment of a relapsed irresectable clear cell renal carcinoma.
Relying on unelected bureaucrats, such as ObamaCare's Independent Payment Advisory Board, to ratchet down Medicare price controls won't control overutilization.
For the second year in a row, the Penn State football team surpassed $90,000 in donations through the Lift for Life fundraiser for the Kidney Cancer Association, totaling $94,410.09 as of Saturday morning's figures.
Biologics are next-generation prescription drugs to treat cancer, rheumatoid arthritis and other debilitating diseases. In November 2010, the Food and Drug Administration began consultation with patient groups, physicians and industry on how to approve the first "generic" versions of these drugs, known as follow-on biologics or biosimilars. As the FDA moves forward in implementing this pathway, the Alliance for Safe Biologic Medicines will work to ensure patient safety remains in the foreground.
Why disease-specific organizations are vital to research, patient support and advocacy
|Powered by NeonCRM|